S&P 500   3,750.87 (-1.80%)
DOW   30,757.40 (-1.64%)
QQQ   303.18 (-1.93%)
AAPL   119.99 (-1.70%)
MSFT   226.42 (-0.50%)
FB   256.94 (+0.60%)
GOOGL   2,021.92 (+0.52%)
TSLA   611.78 (-6.34%)
AMZN   2,982.51 (-0.75%)
NVDA   488.18 (-4.69%)
BABA   230.24 (-2.55%)
CGC   30.62 (-7.88%)
GE   13.40 (-0.30%)
MU   83.09 (-6.76%)
NIO   39.15 (-5.73%)
AMD   77.80 (-3.78%)
T   28.86 (+0.49%)
F   11.85 (-2.63%)
ACB   9.65 (-7.74%)
DIS   186.44 (-3.03%)
BA   223.59 (-2.17%)
NFLX   514.91 (-1.11%)
PFE   34.11 (-0.81%)
S&P 500   3,750.87 (-1.80%)
DOW   30,757.40 (-1.64%)
QQQ   303.18 (-1.93%)
AAPL   119.99 (-1.70%)
MSFT   226.42 (-0.50%)
FB   256.94 (+0.60%)
GOOGL   2,021.92 (+0.52%)
TSLA   611.78 (-6.34%)
AMZN   2,982.51 (-0.75%)
NVDA   488.18 (-4.69%)
BABA   230.24 (-2.55%)
CGC   30.62 (-7.88%)
GE   13.40 (-0.30%)
MU   83.09 (-6.76%)
NIO   39.15 (-5.73%)
AMD   77.80 (-3.78%)
T   28.86 (+0.49%)
F   11.85 (-2.63%)
ACB   9.65 (-7.74%)
DIS   186.44 (-3.03%)
BA   223.59 (-2.17%)
NFLX   514.91 (-1.11%)
PFE   34.11 (-0.81%)
S&P 500   3,750.87 (-1.80%)
DOW   30,757.40 (-1.64%)
QQQ   303.18 (-1.93%)
AAPL   119.99 (-1.70%)
MSFT   226.42 (-0.50%)
FB   256.94 (+0.60%)
GOOGL   2,021.92 (+0.52%)
TSLA   611.78 (-6.34%)
AMZN   2,982.51 (-0.75%)
NVDA   488.18 (-4.69%)
BABA   230.24 (-2.55%)
CGC   30.62 (-7.88%)
GE   13.40 (-0.30%)
MU   83.09 (-6.76%)
NIO   39.15 (-5.73%)
AMD   77.80 (-3.78%)
T   28.86 (+0.49%)
F   11.85 (-2.63%)
ACB   9.65 (-7.74%)
DIS   186.44 (-3.03%)
BA   223.59 (-2.17%)
NFLX   514.91 (-1.11%)
PFE   34.11 (-0.81%)
S&P 500   3,750.87 (-1.80%)
DOW   30,757.40 (-1.64%)
QQQ   303.18 (-1.93%)
AAPL   119.99 (-1.70%)
MSFT   226.42 (-0.50%)
FB   256.94 (+0.60%)
GOOGL   2,021.92 (+0.52%)
TSLA   611.78 (-6.34%)
AMZN   2,982.51 (-0.75%)
NVDA   488.18 (-4.69%)
BABA   230.24 (-2.55%)
CGC   30.62 (-7.88%)
GE   13.40 (-0.30%)
MU   83.09 (-6.76%)
NIO   39.15 (-5.73%)
AMD   77.80 (-3.78%)
T   28.86 (+0.49%)
F   11.85 (-2.63%)
ACB   9.65 (-7.74%)
DIS   186.44 (-3.03%)
BA   223.59 (-2.17%)
NFLX   514.91 (-1.11%)
PFE   34.11 (-0.81%)
Log in
NASDAQ:CRSP

CRISPR Therapeutics Competitors

Followed 187 Times   Searched 732 Times  
$113.25
-5.83 (-4.90 %)
(As of 03/4/2021 01:33 PM ET)
Add
Compare
Today's Range
$111.13
Now: $113.25▼
$122.36
50-Day Range
$125.69
MA: $165.10▼
$210.04
52-Week Range
$32.30
Now: $113.25▼
$220.20
Volume91,292 shs
Average Volume2.46 million shs
Market Capitalization$8.54 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.37

Competitors

CRISPR Therapeutics (NASDAQ:CRSP) Vs. SGEN, BNTX, ARGX, TECH, NVAX, and QGEN

Should you be buying CRSP stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to CRISPR Therapeutics, including Seagen (SGEN), BioNTech (BNTX), argenx (ARGX), Bio-Techne (TECH), Novavax (NVAX), and QIAGEN (QGEN).

CRISPR Therapeutics vs. Seagen Stock

CRISPR Therapeutics (NASDAQ:CRSP) and Seagen (NASDAQ:SGEN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares CRISPR Therapeutics and Seagen's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$289.59 million29.42$66.86 million$1.1796.55
Seagen$916.71 million28.74$-158,650,000.00($1.33)-109.33

CRISPR Therapeutics has higher earnings, but lower revenue than Seagen. Seagen is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CRISPR Therapeutics and Seagen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CRISPR Therapeutics-273.10%-20.72%-18.35%
Seagen25.34%20.46%16.67%

Insider and Institutional Ownership

66.4% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 87.2% of Seagen shares are held by institutional investors. 17.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 31.1% of Seagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for CRISPR Therapeutics and Seagen, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CRISPR Therapeutics241202.56
Seagen151112.67

CRISPR Therapeutics currently has a consensus price target of $150.8125, suggesting a potential upside of 33.51%. Seagen has a consensus price target of $188.4615, suggesting a potential upside of 29.61%. Given CRISPR Therapeutics' higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than Seagen.

Volatility & Risk

CRISPR Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Summary

Seagen beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.

CRISPR Therapeutics vs. BioNTech Stock

CRISPR Therapeutics (NASDAQ:CRSP) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares CRISPR Therapeutics and BioNTech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$289.59 million29.42$66.86 million$1.1796.55
BioNTech$121.63 million187.35$-200,540,000.00($0.95)-99.62

CRISPR Therapeutics has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CRISPR Therapeutics and BioNTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CRISPR Therapeutics-273.10%-20.72%-18.35%
BioNTech-250.12%-66.72%-41.73%

Insider and Institutional Ownership

66.4% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 10.8% of BioNTech shares are held by institutional investors. 17.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for CRISPR Therapeutics and BioNTech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CRISPR Therapeutics241202.56
BioNTech04302.43

CRISPR Therapeutics currently has a consensus price target of $150.8125, suggesting a potential upside of 33.51%. BioNTech has a consensus price target of $102.75, suggesting a potential upside of 8.57%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than BioNTech.

Volatility & Risk

CRISPR Therapeutics has a beta of 2.37, suggesting that its share price is 137% more volatile than the S&P 500. Comparatively, BioNTech has a beta of -1.74, suggesting that its share price is 274% less volatile than the S&P 500.

Summary

CRISPR Therapeutics beats BioNTech on 12 of the 14 factors compared between the two stocks.

CRISPR Therapeutics vs. argenx Stock

argenx (NASDAQ:ARGX) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Risk & Volatility

argenx has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, CRISPR Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.

Profitability

This table compares argenx and CRISPR Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
argenxN/AN/AN/A
CRISPR Therapeutics-273.10%-20.72%-18.35%

Valuation & Earnings

This table compares argenx and CRISPR Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenx$78.17 million177.46$-182,520,000.00($4.73)-61.95
CRISPR Therapeutics$289.59 million29.42$66.86 million$1.1796.55

CRISPR Therapeutics has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for argenx and CRISPR Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
argenx071102.61
CRISPR Therapeutics241202.56

argenx currently has a consensus target price of $286.8235, suggesting a potential downside of 2.11%. CRISPR Therapeutics has a consensus target price of $150.8125, suggesting a potential upside of 33.51%. Given CRISPR Therapeutics' higher probable upside, analysts plainly believe CRISPR Therapeutics is more favorable than argenx.

Insider and Institutional Ownership

54.2% of argenx shares are held by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are held by institutional investors. 17.1% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CRISPR Therapeutics beats argenx on 9 of the 14 factors compared between the two stocks.

CRISPR Therapeutics vs. Bio-Techne Stock

Bio-Techne (NASDAQ:TECH) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Volatility & Risk

Bio-Techne has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Bio-Techne and CRISPR Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne04602.60
CRISPR Therapeutics241202.56

Bio-Techne presently has a consensus target price of $352.30, suggesting a potential upside of 0.66%. CRISPR Therapeutics has a consensus target price of $150.8125, suggesting a potential upside of 33.51%. Given CRISPR Therapeutics' higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than Bio-Techne.

Profitability

This table compares Bio-Techne and CRISPR Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
CRISPR Therapeutics-273.10%-20.72%-18.35%

Insider & Institutional Ownership

93.8% of Bio-Techne shares are held by institutional investors. Comparatively, 66.4% of CRISPR Therapeutics shares are held by institutional investors. 3.8% of Bio-Techne shares are held by insiders. Comparatively, 17.1% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Bio-Techne and CRISPR Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million18.38$229.30 million$3.8690.67
CRISPR Therapeutics$289.59 million29.42$66.86 million$1.1796.55

Bio-Techne has higher revenue and earnings than CRISPR Therapeutics. Bio-Techne is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Techne beats CRISPR Therapeutics on 9 of the 14 factors compared between the two stocks.

CRISPR Therapeutics vs. Novavax Stock

CRISPR Therapeutics (NASDAQ:CRSP) and Novavax (NASDAQ:NVAX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Volatility & Risk

CRISPR Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, Novavax has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CRISPR Therapeutics and Novavax, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CRISPR Therapeutics241202.56
Novavax10602.71

CRISPR Therapeutics presently has a consensus price target of $150.8125, indicating a potential upside of 33.51%. Novavax has a consensus price target of $213.9286, indicating a potential upside of 34.36%. Given Novavax's stronger consensus rating and higher probable upside, analysts plainly believe Novavax is more favorable than CRISPR Therapeutics.

Profitability

This table compares CRISPR Therapeutics and Novavax's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CRISPR Therapeutics-273.10%-20.72%-18.35%
Novavax-133.10%-1,346.17%-45.85%

Insider and Institutional Ownership

66.4% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 49.9% of Novavax shares are owned by institutional investors. 17.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 3.3% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares CRISPR Therapeutics and Novavax's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$289.59 million29.42$66.86 million$1.1796.55
Novavax$18.66 million550.80$-132,690,000.00($5.80)-27.84

CRISPR Therapeutics has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

CRISPR Therapeutics beats Novavax on 9 of the 14 factors compared between the two stocks.

CRISPR Therapeutics vs. QIAGEN Stock

CRISPR Therapeutics (NASDAQ:CRSP) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CRISPR Therapeutics and QIAGEN, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CRISPR Therapeutics241202.56
QIAGEN16902.50

CRISPR Therapeutics presently has a consensus price target of $150.8125, indicating a potential upside of 33.51%. QIAGEN has a consensus price target of $56.3689, indicating a potential upside of 18.67%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe CRISPR Therapeutics is more favorable than QIAGEN.

Volatility & Risk

CRISPR Therapeutics has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Profitability

This table compares CRISPR Therapeutics and QIAGEN's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CRISPR Therapeutics-273.10%-20.72%-18.35%
QIAGEN11.18%17.51%8.44%

Earnings & Valuation

This table compares CRISPR Therapeutics and QIAGEN's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$289.59 million29.42$66.86 million$1.1796.55
QIAGEN$1.53 billion7.09$-41,460,000.00$1.4333.22

CRISPR Therapeutics has higher earnings, but lower revenue than QIAGEN. QIAGEN is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

66.4% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 43.6% of QIAGEN shares are owned by institutional investors. 17.1% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 9.0% of QIAGEN shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CRISPR Therapeutics beats QIAGEN on 8 of the 14 factors compared between the two stocks.

pixel
Ad Investing Daily
We're pulling 69%/yr -- without margin, options, or gimmicks
I only buy one kind of stock. 37 of these cash cows are in my portfolio right now... and for every dollar invested in them they are sending us 69 cents in dividends. That's an effective yield of 69% a year-every year.

CRISPR Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Seagen logo
SGEN
Seagen
1.7$145.41-1.7%$26.80 billion$916.71 million57.25Decrease in Short Interest
BioNTech logo
BNTX
BioNTech
0.9$94.64-2.8%$23.42 billion$121.63 million-47.32Decrease in Short Interest
argenx logo
ARGX
argenx
1.1$293.01-7.9%$14.97 billion$78.17 million-61.95News Coverage
Gap Up
Bio-Techne logo
TECH
Bio-Techne
1.8$350.00-3.2%$14.02 billion$738.69 million56.00Analyst Upgrade
Novavax logo
NVAX
Novavax
1.4$161.45-13.7%$11.69 billion$18.66 million-30.93Earnings Announcement
Insider Selling
Analyst Revision
Gap Up
QIAGEN logo
QGEN
QIAGEN
1.7$47.50-3.4%$11.18 billion$1.53 billion58.64News Coverage
Gap Up
Repligen logo
RGEN
Repligen
1.5$185.08-8.0%$10.95 billion$270.24 million225.71Analyst Report
Analyst Revision
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.64-2.6%$8.93 billion$788.10 million99.61Unusual Options Activity
Analyst Revision
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$81.98-7.9%$8.30 billion$10.68 million-44.55Analyst Report
Analyst Revision
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.4$127.78-1.9%$7.89 billion$73.99 million-49.34Earnings Announcement
Analyst Report
Analyst Revision
News Coverage

Buffett Dumps $800M Of Apple, Buys This Instead! (Ad)

Warren Buffett recently dumped $800 million of Apple stock…

He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…

What does Buffett know?
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.1$58.94-4.1%$7.42 billion$26.68 million-26.67Earnings Announcement
Analyst Report
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$45.12-11.2%$6.98 billion$85.07 million-47.49Analyst Downgrade
Insider Selling
Twist Bioscience logo
TWST
Twist Bioscience
1.4$117.38-10.8%$6.32 billion$90.10 million-31.30
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.14-4.5%$5.67 billion$195.99 million250.88Insider Selling
Gap Up
Vir Biotechnology logo
VIR
Vir Biotechnology
1.6$36.08-15.8%$5.34 billion$8.09 million-15.29Analyst Report
News Coverage
Gap Up
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$109.77-5.0%$5.16 billionN/A-47.31Earnings Announcement
Analyst Downgrade
Analyst Revision
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$31.93-7.1%$5.03 billionN/A-16.63Analyst Report
Analyst Revision
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$73.03-14.7%$4.86 billion$20,000.00-5.20Analyst Downgrade
Analyst Revision
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$31.88-3.8%$4.65 billionN/A-14.97Analyst Report
Analyst Revision
China Biologic Products logo
CBPO
China Biologic Products
0.8$117.89-0.1%$4.64 billion$503.70 million32.93Upcoming Earnings
Increase in Short Interest
News Coverage
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$70.17-6.5%$3.66 billionN/A-40.33Earnings Announcement
Analyst Report
RLAY
Relay Therapeutics
1.8$40.02-3.6%$3.47 billionN/A0.00
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$63.10-9.2%$3.04 billion$125.57 million-36.90Earnings Announcement
Analyst Report
Gap Up
Editas Medicine logo
EDIT
Editas Medicine
1.4$38.72-11.4%$2.91 billion$20.53 million-22.25Earnings Announcement
Analyst Downgrade
Analyst Revision
Gap Up
NantKwest logo
NK
NantKwest
1.1$24.21-9.8%$2.90 billion$40,000.00-34.10Decrease in Short Interest
Revolution Medicines logo
RVMD
Revolution Medicines
1.6$41.91-0.4%$2.77 billion$50.04 million0.00Earnings Announcement
Analyst Report
News Coverage
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$8.49-6.8%$2.55 billion$31.43 million-5.82Gap Up
AlloVir logo
ALVR
AlloVir
1.4$34.89-6.4%$2.42 billionN/A0.00Insider Selling
News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$11.06-7.3%$2.10 billion$48.83 million-14.55Analyst Report
Analyst Revision
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.8$44.62-0.9%$2.00 billionN/A0.00

This Gold Player May Have Found the Biggest Gold Strike (Ad)

With physical demand for gold set to pick up in 2021 and a strong tailwind from stimulus measures, gold related stocks may skyrocket including this emerging player sitting on a high-grade motherlode!pixel

Continue Reading
bluebird bio logo
BLUE
bluebird bio
1.8$28.15-4.2%$1.97 billion$44.67 million-2.56Analyst Report
Gap Up
Ocugen logo
OCGN
Ocugen
1.1$8.76-19.4%$1.97 billionN/A-5.92Analyst Report
Unusual Options Activity
Gap Up
Vericel logo
VCEL
Vericel
1.5$40.42-4.2%$1.93 billion$117.85 million-4,042,000.00Analyst Report
Analyst Revision
Gap Up
Scholar Rock logo
SRRK
Scholar Rock
1.3$48.86-5.4%$1.73 billion$20.49 million-20.27Upcoming Earnings
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.1$39.33-1.9%$1.72 billionN/A0.00News Coverage
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$75.69-10.0%$1.64 billionN/A-51.14Earnings Announcement
Analyst Report
Analyst Revision
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.11-0.8%$1.60 billion$102.43 million-18.52Analyst Downgrade
Analyst Revision
News Coverage
Translate Bio logo
TBIO
Translate Bio
1.4$20.84-2.9%$1.59 billion$7.80 million-19.48Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Replimune Group logo
REPL
Replimune Group
1.5$31.63-3.5%$1.52 billionN/A-17.87News Coverage
REGENXBIO logo
RGNX
REGENXBIO
1.8$38.84-3.3%$1.50 billion$35.23 million-15.66Earnings Announcement
Analyst Downgrade
Analyst Revision
FMTX
Forma Therapeutics
1.8$34.22-5.9%$1.49 billion$100.56 million0.00Decrease in Short Interest
News Coverage
Immunovant logo
IMVT
Immunovant
1.8$13.31-5.1%$1.37 billionN/A-10.32Increase in Short Interest
PCVX
Vaxcyte
1.8$24.11-7.1%$1.32 billionN/A0.00Insider Selling
Alector logo
ALEC
Alector
1.3$15.45-6.2%$1.31 billion$21.22 million-6.93Earnings Announcement
Analyst Upgrade
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$15.36-3.8%$1.24 billionN/A-3.32Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.33-0.7%$1.12 billion$356.07 million7.51Analyst Report
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$11.01-2.6%$1.10 billion$250,000.00-8.67Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Inhibrx logo
INBX
Inhibrx
1.7$26.05-12.1%$1.10 billionN/A0.00Upcoming Earnings
Mesoblast logo
MESO
Mesoblast
1.4$9.14-0.1%$1.08 billion$32.16 million-10.39Earnings Announcement
Analyst Revision
Cortexyme logo
CRTX
Cortexyme
1.3$33.93-3.7%$1.04 billionN/A-14.14Earnings Announcement
Gap Up
This page was last updated on 3/4/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.